Perigon Wealth Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-11,290
Closed -$226K – 1046
2024
Q3
$226K Buy
11,290
+41
+0.4% +$638 0.01% 892
2024
Q2
$126K Hold
11,249
– – ﹤0.01% 836
2024
Q1
$74.2K Hold
11,249
– – ﹤0.01% 837
2023
Q4
$50.8K Hold
11,249
– – ﹤0.01% 821
2023
Q3
$40.3K Sell
11,249
-1,158
-9% -$4.46K ﹤0.01% 769
2023
Q2
$45.8K Buy
+12,407
New +$46K ﹤0.01% 767

Other funds holding ADMA

Perigon Wealth Management's ADMA Position: Q4 2024 in Review

Perigon Wealth Management sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 11,290 shares — an estimated $226K sold.

Perigon Wealth Management first reported a position in ADMA in Q2 2023 and held it in 6 quarters. The position peaked at $226K in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Perigon Wealth Management reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Perigon Wealth Management sold 11,290 ADMA Biologics shares in Q4 2024, an estimated $226K.
  • Perigon Wealth Management first reported a position in ADMA Biologics in Q2 2023 and held it in 6 quarters.
  • Perigon Wealth Management's ADMA Biologics position peaked at $226K in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Perigon Wealth Management's 13F filing for Q4 2024, filed 22 Jan 2025.